Pro-inflammatory HDL (piHDL) may help predict risk of atherosclerosis (ATH) in patients with systemic lupus erythematosus (SLE). The study found 45% of SLE patients and none of the healthy controls had piHDL. PiHDL was significantly associated with carotid plaque and greatly increased the risk of plaque in SLE patients. Traditional risk factors did not fully explain the risk of ATH in SLE. PiHDL could be a useful marker for predicting ATH risk in SLE patients. Further research is needed to develop new treatments targeting piHDL and risk profiles including piHDL.